α-1-acid glycoprotein as a predictive biomarker for severe neutropenia induced by docetaxel in esophageal carcinoma

被引：0
作者：
Sasaki, Yusuke [1 ]
Kato, Ken [1 ]
Shoji, Hirokazu [1 ]
Iwasa, Satoru [1 ]
Hamaguchi, Tetsuya [1 ]
Boku, Narikazu [1 ]
机构：
[1] Natl Canc Ctr, Gastrointest Oncol Div, Tokyo, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
alpha 1 acid glycoprotein; Docetaxel;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2249
引用
收藏
页码：692 / 692
页数：1
相关论文
共 25 条
  • [11] Docetaxel serum protein binding with high affinity to alpha(1)-acid glycoprotein
    Urien, S
    Barre, J
    Morin, C
    Paccaly, A
    Montay, G
    Tillement, JP
    INVESTIGATIONAL NEW DRUGS, 1996, 14 (02) : 147 - 151
  • [12] Association between pharmacokinetic variables and neutropenia after treatment with docetaxel, cisplatin, and 5-fluorouracil in patients with esophageal squamous cell carcinoma
    Sugawara, Mitsuhiro
    Katada, Chikatoshi
    Komatsu, Toshiaki
    Takahashi, Kaoru
    Azuma, Mizutomo
    Higuchi, Katsuhiko
    Koizumi, Wasaburo
    Atsuda, Koichiro
    ESOPHAGUS, 2015, 12 (03) : 209 - 218
  • [13] Association between pharmacokinetic variables and neutropenia after treatment with docetaxel, cisplatin, and 5-fluorouracil in patients with esophageal squamous cell carcinoma
    Mitsuhiro Sugawara
    Chikatoshi Katada
    Toshiaki Komatsu
    Kaoru Takahashi
    Mizutomo Azuma
    Katsuhiko Higuchi
    Wasaburo Koizumi
    Koichiro Atsuda
    Esophagus, 2015, 12 : 209 - 218
  • [14] Docetaxel-induced severe neuropathy, a case of breast cancer with GTSP1 polymorphism
    Degerli, Ezgi
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2025, 31 (02) : 325 - 328
  • [15] Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma
    Tanaka, Yoshihiro
    Yoshida, Kazuhiro
    Tanahashi, Toshiyuki
    Okumura, Naoki
    Matsuhashi, Nobuhisa
    Yamaguchi, Kazuya
    CANCER SCIENCE, 2016, 107 (06): : 764 - 772
  • [16] Postoperative radiotherapy with docetaxel versus cisplatin for high-risk oral squamous cell carcinoma: a randomized phase II trial with exploratory analysis of ITGB1 as a potential predictive biomarker
    Jiang, Wen
    Chen, Lan
    Li, Rongrong
    Li, Jiang
    Dou, Shengjin
    Ye, Lulu
    He, Yining
    Tian, Zhen
    Yao, Yanli
    Zhu, Guopei
    BMC MEDICINE, 2024, 22 (01):
  • [17] Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
    Zhou, Xi-Lei
    Yu, Chang-Hua
    Wang, Wan-Wei
    Ji, Fu-Zhi
    Xiong, Yao-Zu
    Zhu, Wei-Guo
    Tong, Yu-Suo
    RADIATION ONCOLOGY, 2021, 16 (01)
  • [18] Docetaxel, Nedaplatin, and S-1 (DGS) Chemotherapy for Advanced Esophageal Carcinoma: A Phase I Dose-escalation Study
    Tanaka, Yoshihiro
    Yoshida, Kazuhiro
    Osada, Shinji
    Yamaguchi, Kazuya
    Takahashi, Takao
    ANTICANCER RESEARCH, 2011, 31 (12) : 4589 - 4597
  • [19] Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
    Xi-Lei Zhou
    Chang-Hua Yu
    Wan-Wei Wang
    Fu-Zhi Ji
    Yao-Zu Xiong
    Wei-Guo Zhu
    Yu-Suo Tong
    Radiation Oncology, 16
  • [20] Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation
    Kitabayashi, H
    Shimada, H
    Yamada, S
    Yasuda, S
    Kamata, T
    Ando, K
    Tsujii, H
    Ochiai, T
    ONCOLOGY REPORTS, 2006, 15 (04) : 913 - 918
123